ArticleVirology journal2025
A phage-displayed nanobody-based competitive immunoassay for the detection of African swine fever virus antibodies.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation.Antibodies (Basel, Switzerland) · 2026Article
- A broadly applicable split-luciferase biosensor approach for rapid antibody detection in emerging infectious diseases.Applied microbiology and biotechnology · 2026Article
- The application of bacteriophage to veterinary and One-Health medicine-a road map.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
African swine fever (ASF) is a highly infectious and devastating disease that poses a significant threat to the global swine industry. The rapid spread of ASF and its ongoing pandemics continue to impact pig farming worldwide. The absence of an effective vaccine, coupled with the complexity of the African swine fever virus (ASFV), makes the control and eradication of ASF a formidable challenge. Nanobodies, derived from camelids, have emerged as promising alternatives to conventional monoclonal antibodies, offering distinct advantages in various biological applications. In this study, specific nanobodies targeting the ASFV K205R protein were selected from a phage-displayed immune library. Ten individual nanobodies were isolated based on their complementary determining regions (CDRs), and four were found to bind to the naive K205R protein of ASFV. After evaluation, nanobody VHH1 was selected for the development of a competitive enzyme-linked immunosorbent assay (ELISA) for ASFV antibody detection. The assay was optimized for various reaction conditions, and the cut-off value was determined to be 26.85%, with diagnostic sensitivity and specificity of 97.52% and 97.48%, respectively. No cross-reactivity was observed with sera from pigs infected with other swine viruses, and the assay exhibited a detection sensitivity of 1:128. Comparative analysis of clinical samples showed a high concordance rate (98.98%) between the nanobody-based and monoclonal antibody-based ELISAs (Mab-cELISA). In conclusion, this study presents a phage-displayed nanobody-based competitive ELISA for the detection of ASFV antibodies, which could be valuable for ASF sero-surveillance. Additionally, the K205R-specific nanobodies identified here may be adapted for other biological or biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.